Vol 9, Supp. A (2018)
Case report
Published online: 2019-06-07

open access

Page views 442
Article views/downloads 557
Get Citation

Connect on Social Media

Connect on Social Media

Treatment of patients with chronic myelogenous leukemia with tyrosine kinase inhibitors — skirmishes with side effects of medications

Justyna Gil1
DOI: 10.5603/Hem.2018.0008

Abstract

A 42-year-old woman diagnosed with chronic myelogenous leukemia in the chronic phase in July 2012, initially treated with imatinib followed by dasatinib due to a lack of partial cytogenetic response after 6 months of treatment. Molecular and cytogenetic response was obtained. In May and then in August 2013, fluid occurred in both pleural cavities with strong dyspnea. Despite the reduction of the tyrosine kinase inhibitor, use of diuretics and steroid therapy resolution of the fluid was not obtained and after the second episode in August 2013 nilotinib was included in the dose of 800 mg/day. In December 2014, hyperbilirubinemia due to nilotinib was observed. The dose of the drug was reduced to 400 mg/day with good effect and maintenance of the molecular response.

Article available in PDF format

View PDF (Polish) Download PDF file



Hematology in Clinical Practice